falsefalse

EGFR mutated NSCLC: Treatment Advances and Highlights from ASCO 2025 - Episode 3

MARIPOSA: Clinical Implications of Updated Key Data

, , , ,

Panelists discuss the Mariposa trial’s landmark overall survival benefit with amivantamab plus lazertinib over osimertinib monotherapy in EGFR-mutant NSCLC, marking a paradigm shift toward durable survival and reinforcing the value of optimized patient selection and adherence to combination regimens.

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected

    The recent update from the Mariposa trial, presented at the 2025 European Lung Cancer Conference, brought significant excitement to the field of EGFR-mutant non-small cell lung cancer. The trial compared the combination of amivantamab with lazertinib against osimertinib monotherapy and showed a statistically significant improvement in overall survival (OS). Importantly, the control arm’s OS of just over three years was consistent with previous studies and real-world experience, providing confidence in the integrity of the comparison.

    What stood out most was that the combination arm had not even reached median overall survival at the time of analysis, suggesting a meaningful extension in patient longevity. Early interpretation indicates the potential for a survival benefit exceeding one year over osimertinib alone. This magnitude of improvement is considered highly impactful and reinforces the growing belief that more aggressive targeted combinations can reshape outcomes in this setting.

    The final takeaway emphasized the importance of overall survival as the gold standard for evaluating treatments in the metastatic setting. The data mark a shift in what’s possible for patients, making long-term survival a more realistic goal. The results also underscore the importance of selecting the right patients for combination therapies and sticking closely to the studied regimens to ensure optimal benefit.

    x